kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
796
JPY
0
(0.00%)
Jan 29, 3:10 pm JST
5.19
USD
Jan 29, 1:10 am EST
Result
PTS
outside of trading hours
794.8
Jan 29, 3:11 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.10
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
785 JPY 5.12 USD
Previous Close Jan 28
796 JPY 5.21 USD
High Jan 29, 3:10 pm
796 JPY 5.19 USD
Low Jan 29, 9:35 am
777 JPY 5.08 USD
Volume
482,100
Trading Value
0.38B JPY 2.47M USD
VWAP
784.99 JPY 5.13 USD
Minimum Trading Value
79,600 JPY 519 USD
Market Cap
0.07T JPY 0.47B USD
Number of Trades
742
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,313
1-Year High Dec 19, 2025
6,833
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 184,700 6,269,900 33.95
Jan 16, 2026 175,200 6,422,200 36.66
Jan 9, 2026 195,700 5,947,400 30.39
Dec 26, 2025 178,700 6,198,200 34.68
Dec 19, 2025 199,700 6,548,200 32.79
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.